HCW Biologics (HCWB) Competitors

$3.16 +0.58 (+22.64%)

As of 01:56 PM Eastern

HCWB vs. CURX, GDTC, GNPX, PMCB, and ADXN

Should you buy HCW Biologics stock or one of its competitors? MarketBeat compares HCW Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HCW Biologics include Curanex Pharmaceuticals (CURX), CytoMed Therapeutics (GDTC), Genprex (GNPX), Nuvilex (PMCB), and Addex Therapeutics (ADXN). These companies are all part of the "pharmaceutical products" industry.

How does HCW Biologics compare to Curanex Pharmaceuticals?

HCW Biologics (NASDAQ:HCWB) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Curanex Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Curanex Pharmaceuticals' return on equity of -85.41% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

HCW Biologics currently has a consensus price target of $35.00, indicating a potential upside of 1,006.19%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts plainly believe HCW Biologics is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.0% of HCW Biologics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Curanex Pharmaceuticals has lower revenue, but higher earnings than HCW Biologics. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$6.59M	3.23	-$7.96M	-$9.46	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

In the previous week, HCW Biologics had 8 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 12 mentions for HCW Biologics and 4 mentions for Curanex Pharmaceuticals. HCW Biologics' average media sentiment score of 0.19 beat Curanex Pharmaceuticals' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Curanex Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

HCW Biologics beats Curanex Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does HCW Biologics compare to CytoMed Therapeutics?

HCW Biologics (NASDAQ:HCWB) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

In the previous week, HCW Biologics had 11 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 12 mentions for HCW Biologics and 1 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.75 beat HCW Biologics' score of 0.19 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HCW Biologics currently has a consensus target price of $35.00, suggesting a potential upside of 1,006.19%. Given HCW Biologics' stronger consensus rating and higher probable upside, research analysts clearly believe HCW Biologics is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics has lower revenue, but higher earnings than HCW Biologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$6.59M	3.23	-$7.96M	-$9.46	N/A
CytoMed Therapeutics	$250K	54.65	-$3.10M	N/A	N/A

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CytoMed Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. CytoMed Therapeutics' return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
CytoMed Therapeutics	N/A	N/A	N/A

HCW Biologics has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market.

Summary

HCW Biologics beats CytoMed Therapeutics on 8 of the 14 factors compared between the two stocks.

How does HCW Biologics compare to Genprex?

HCW Biologics (NASDAQ:HCWB) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

HCW Biologics presently has a consensus target price of $35.00, indicating a potential upside of 1,006.19%. Given HCW Biologics' stronger consensus rating and higher probable upside, research analysts plainly believe HCW Biologics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genprex has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Genprex's return on equity of -247.32% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Genprex	N/A	-247.32%	-176.73%

HCW Biologics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Genprex has a beta of -0.94, suggesting that its share price is 194% less volatile than the broader market.

HCW Biologics has higher revenue and earnings than Genprex. HCW Biologics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$6.59M	3.23	-$7.96M	-$9.46	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

In the previous week, HCW Biologics had 11 more articles in the media than Genprex. MarketBeat recorded 12 mentions for HCW Biologics and 1 mentions for Genprex. Genprex's average media sentiment score of 0.61 beat HCW Biologics' score of 0.19 indicating that Genprex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genprex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

HCW Biologics beats Genprex on 10 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to Nuvilex?

HCW Biologics (NASDAQ:HCWB) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

HCW Biologics presently has a consensus target price of $35.00, suggesting a potential upside of 1,006.19%. Given HCW Biologics' stronger consensus rating and higher possible upside, research analysts clearly believe HCW Biologics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 11.0% of Nuvilex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, HCW Biologics had 12 more articles in the media than Nuvilex. MarketBeat recorded 12 mentions for HCW Biologics and 0 mentions for Nuvilex. HCW Biologics' average media sentiment score of 0.19 beat Nuvilex's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
HCW Biologics	Neutral
Nuvilex	Neutral

Nuvilex has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Nuvilex's return on equity of 2.13% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Nuvilex	N/A	2.13%	1.69%

HCW Biologics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Nuvilex has lower revenue, but higher earnings than HCW Biologics. Nuvilex is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$6.59M	3.23	-$7.96M	-$9.46	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Summary

HCW Biologics beats Nuvilex on 8 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to Addex Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Addex Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Addex Therapeutics' return on equity of -80.69% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-80.69%	-69.69%
HCW Biologics	-34.73%	-486.87%	-29.19%

HCW Biologics has a consensus price target of $35.00, indicating a potential upside of 1,006.19%. Given HCW Biologics' stronger consensus rating and higher possible upside, analysts clearly believe HCW Biologics is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Addex Therapeutics has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, HCW Biologics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

In the previous week, HCW Biologics had 11 more articles in the media than Addex Therapeutics. MarketBeat recorded 12 mentions for HCW Biologics and 1 mentions for Addex Therapeutics. HCW Biologics' average media sentiment score of 0.19 beat Addex Therapeutics' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HCW Biologics	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Addex Therapeutics has higher earnings, but lower revenue than HCW Biologics. Addex Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	41.56	$8.02M	-$5.74	N/A
HCW Biologics	$6.59M	3.23	-$7.96M	-$9.46	N/A

Summary

Addex Therapeutics and HCW Biologics tied by winning 8 of the 16 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCWB vs. The Competition

Export

Metric	HCW Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.25M	$3.38B	$6.38B	$12.34B
Dividend Yield	N/A	2.30%	2.79%	5.33%
P/E Ratio	-0.33	19.04	20.91	25.65
Price / Sales	3.23	298.20	543.80	85.61
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	3.68	6.98	10.09	7.06
Net Income	-$7.96M	$24.45M	$3.55B	$335.04M
7 Day Performance	159.34%	3.54%	4.71%	2.60%
1 Month Performance	692.98%	-0.26%	1.43%	1.42%
1 Year Performance	-61.93%	62.90%	36.72%	35.67%

HCW Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCWB HCW Biologics	1.7329 of 5 stars	$3.16 +22.6%	$35.00 +1,006.2%	-70.3%	$21.25M	$6.59M	N/A	40	News Coverage Gap Up
CURX Curanex Pharmaceuticals	0.5462 of 5 stars	$0.32 -3.7%	N/A	N/A	$8.94M	N/A	N/A	N/A	Gap Down
GDTC CytoMed Therapeutics	0.4533 of 5 stars	$0.76 -1.9%	N/A	-41.9%	$8.93M	$250K	N/A	N/A	News Coverage
GNPX Genprex	0.6658 of 5 stars	$0.85 +2.5%	N/A	-94.1%	$8.87M	N/A	N/A	20	Gap Up
PMCB Nuvilex	0.4115 of 5 stars	$0.81 +2.8%	N/A	-23.5%	$8.72M	N/A	N/A	4	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCWB) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCW Biologics (HCWB) Competitors

HCWB vs. CURX, GDTC, GNPX, PMCB, and ADXN

How does HCW Biologics compare to Curanex Pharmaceuticals?

Summary

How does HCW Biologics compare to CytoMed Therapeutics?

Summary

How does HCW Biologics compare to Genprex?

Summary

How does HCW Biologics compare to Nuvilex?

Summary

How does HCW Biologics compare to Addex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HCW Biologics (HCWB) Competitors

HCWB vs. CURX, GDTC, GNPX, PMCB, and ADXN

How does HCW Biologics compare to Curanex Pharmaceuticals?

Is HCWB or CURX more profitable?

Do analysts recommend HCWB or CURX?

Do insiders and institutionals have more ownership in HCWB or CURX?

Which has preferable earnings and valuation, HCWB or CURX?

Does the media favor HCWB or CURX?

Summary

How does HCW Biologics compare to CytoMed Therapeutics?

Does the media refer more to HCWB or GDTC?

Do analysts recommend HCWB or GDTC?

Which has stronger valuation & earnings, HCWB or GDTC?

Do institutionals and insiders hold more shares of HCWB or GDTC?

Is HCWB or GDTC more profitable?

Which has more risk and volatility, HCWB or GDTC?

Summary

How does HCW Biologics compare to Genprex?

Do analysts prefer HCWB or GNPX?

Do institutionals and insiders believe in HCWB or GNPX?

Is HCWB or GNPX more profitable?

Which has more risk and volatility, HCWB or GNPX?

Which has better valuation & earnings, HCWB or GNPX?

Does the media favor HCWB or GNPX?

Summary

How does HCW Biologics compare to Nuvilex?

Do analysts rate HCWB or PMCB?

Do insiders & institutionals have more ownership in HCWB or PMCB?

Does the media favor HCWB or PMCB?

Is HCWB or PMCB more profitable?

Which has more volatility and risk, HCWB or PMCB?

Which has preferable earnings and valuation, HCWB or PMCB?

Summary

How does HCW Biologics compare to Addex Therapeutics?

Do insiders and institutionals have more ownership in ADXN or HCWB?

Is ADXN or HCWB more profitable?

Do analysts rate ADXN or HCWB?

Which has more volatility & risk, ADXN or HCWB?

Does the media prefer ADXN or HCWB?

Which has higher earnings and valuation, ADXN or HCWB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools